Low molecular weight heparin, reviparin, in prevention of restenosis after percutaneous transluminal coronary angioplasty Results of the REDUCE trial
Preisack, M.B.; Karsch, K.R.; Bonan, R.
European Heart Journal 17(ABSTR Suppl ): 119
1996
ISSN/ISBN: 0195-668X Accession: 032203824
PDF emailed within 1 workday: $29.90
Related References
Karsch, K.R.; Preisack, M.B.; Baildon, R.; Eschenfelder, V.; Foley, D.; Garcia, E.J.; Kaltenbach, M.; Meisner, C.; Selbmann, H.K.; Serruys, P.W.; Shiu, M.F.; Sujatta, M.; Bonan, R. 1996: Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation Journal of the American College of Cardiology 28(6): 1437-1443Schmid, K.M.; Preisack, M.; Voelker, W.; Sujatta, M.; Karsch, K.R. 1993: First clinical experience with low molecular weight heparin LU 47311 (reviparin) for prevention of restenosis after percutaneous transluminal coronary angioplasty Seminars in Thrombosis and Hemostasis 19 Suppl. 1: 155-159
Karsch, K.R.; Preisack, M.B.; Bonan, R. 1996: Low Molecular weight heparin, reviparin, in prevention of restenosis after PTCA Results of the reduce trial Journal of the American College of Cardiology 27(2 Suppl A): 113A
Preisack, M.B.; Bonan, R.; Meisner, C.; Eschenfelder, V.; Karsch, K.R. 1998: Incidence, outcome and prediction of early clinical events following percutaneous transluminal coronary angioplasty. A comparison between treatment with reviparin and unfractionated heparin/placebo (results of a substudy of the REDUCE trial) European Heart Journal 19(8): 1232-1238
Schmid, K.M.; Preisack, M.; Voelker, W.; Sujatta, M.; Karsch, K.R. 1993: First clinical experience with low molecular weight heparin LU-47311 for prevention of restenosis after percutaneous transluminal coronary angioplasty Seminars in Thrombosis and Hemostasis 19(Suppl 1): 155-159
Koppensteiner, R.; Spring, S.; Amann-Vesti, Béatrice.R.; Meier, T.; Pfammatter, T.; Rousson, V.; Banyai, M.; van der Loo, B. 2006: Low-molecular-weight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty: a randomized controlled trial Journal of Vascular Surgery 44(6): 1247-1253
Moneta, G.L. 2008: Low-molecular-weight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty: A randomized controlled trial Yearbook of Vascular Surgery 2008: 216-217
Lorrie Costantini; John Gill; John Cairns; Robin Roberts; Michael Gent 1990: 58 Methodologic issues in a randomized trial to evaluate the effects of omega-3 polyunsaturated fatty acids and low-molecular-weight heparin on restenosis following percutaneous transluminal coronary angioplasty Controlled Clinical Trials 11(4): 276-277
Preisack, M.B.; Karsch, K.R. 1993: Experimental and early clinical experience with reviparin-sodium for prevention of restenosis after percutaneous transluminal coronary angioplasty Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 4(Suppl): S55
Gimple, L.W.; Herrmann, H.C.; Winniford, M.; Mammen, E. 1999: Usefulness of subcutaneous low molecular weight heparin (ardeparin) for reduction of restenosis after percutaneous transluminal coronary angioplasty American Journal of Cardiology 83(11): 1524-1529
Cairns, J.A.; Gill, J.; Morton, B.; Roberts, R.; Gent, M.; Hirsh, J.; Holder, D.; Finnie, K.; Marquis, J.F.; Naqvi, S.; Cohen, E. 1996: Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR Study Circulation 94(7): 1553-1560
Faxon, D.P.; Spiro, T.E.; Minor, S.; Coté, G.; Douglas, J.; Gottlieb, R.; Califf, R.; Dorosti, K.; Topol, E.; Gordon, J.B. 1994: Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial Circulation 90(2): 908-914
Lablanche, Jean Marc 1995: Low Molecular Weight Heparin in the Prevention of Restenosis After Coronary Angioplasty Results of the FACT Study Journal of the American College of Cardiology 1995(SPEC ISSUE): 226A
Herrman, J.-P. R.; Simon, R.; Umans, V. A. W. M.; Peerboom, P. F.; Keane, D.; Rijnierse, J. J. M. M.; Bach, D.; Kobi, P.; Kerry, R.; Close, P.; Deckers, J. W.; Serruys, P. W. 1995: Evaluation of recombinant hirudin (CGP 39 393/TM REVASC) in the prevention of restenosis after percutaneous transluminal coronary angioplasty: Rationale and design of the HELVETICA trial, a multicentre randomized double blind heparin controlled study European Heart Journal 16(Suppl L): 56-62
Herrman, J.P.; Simon, R.; Umans, V.A.; Peerboom, P.F.; Keane, D.; Rijnierse, J.J.; Bach, D.; Kobi, P.; Kerry, R.; Close, P. 1995: Evaluation of recombinant hirudin (CGP 39,393/TMREVASC) in the prevention of restenosis after percutaneous transluminal coronary angioplasty. Rationale and design of the HELVETICA trial, a multicentre randomized double blind heparin controlled study European Heart Journal 16 Suppl L: 56-62